Drug Shortage Report for MILRINONE LACTATE INJECTION, USP
Report ID | 166127 |
Drug Identification Number | 02244622 |
Brand name | MILRINONE LACTATE INJECTION, USP |
Common or Proper name | MILRINONE LACTATE INJECTION, USP |
Company Name | FRESENIUS KABI CANADA LTD |
Market Status | MARKETED |
Active Ingredient(s) | MILRINONE |
Strength(s) | 1MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAVENOUS INTRAVENOUS |
Packaging size | 20mL |
ATC code | C01CE |
ATC description | CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | 2022-08-01 |
Actual start date | 2022-08-01 |
Estimated end date | 2022-10-31 |
Actual end date | 2022-11-01 |
Shortage status | Resolved |
Updated date | 2022-11-02 |
Company comments | Fresenius Kabi Canada regrets to advise that due to a production delay, we will be facing a supply interruption on our Milrinone Lactate Injection 1 mg/mL SD Vial 20 mL effective August 1, 2022 until October 31, 2022. Contract customers will be allocated 100% of historical monthly demand of the 10 mL plus 100% of the 20 mL on a mL per mL basis. Allocations for August will be prorated for the remainder of the month, which equates to 50% of monthly allocations. Effective September 1, 2022, contract customers will have access to their full monthly allocations. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 165 GALAXY BLVD, SUITE 100 TORONTO, ONTARIO CANADA M9W 0C8 |
Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v8 | 2022-11-02 | French | Compare |
v7 | 2022-11-02 | English | Compare |
v6 | 2022-09-19 | French | Compare |
v5 | 2022-09-19 | English | Compare |
v4 | 2022-08-24 | French | Compare |
v3 | 2022-08-24 | English | Compare |
v2 | 2022-08-04 | French | Compare |
v1 | 2022-08-04 | English | Compare |
Showing 1 to 8 of 8